Reminyl Will Receive New Name

FEBRUARY 01, 2005

Johnson & Johnson is renaming its Alzheimer's disease drug Reminyl (galantamine HBr). Although the company and the FDA have not agreed on the new name, the change is expected to be introduced by the end of March 2005. The decision to change Reminyl's name comes after 2 patients died when they were mistakenly given a similar-sounding drug—Amaryl (glimepiride). Amaryl (Sanofi-Aventis) is indicated for the treatment of diabetes. The deaths were caused by hypoglycemia or low blood sugar when the patients were given Amaryl.



SHARE THIS SHARE THIS
0
Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.